Health Condition 1: K053- Chronic periodontitis
Conditions
Interventions
Intervention1: non-surgical periodontal therapy [NSPT] with supplementation of Moringa oleifera: Standard of care: non-surgical periodontal therapy [NSPT] at baseline with supplementation of Moringa o
Sponsors
MGM Institute of Health Sciences
Eligibility
Inclusion criteria
Inclusion criteria: 1. Systemically healthy participants above age of 18 years to 65 years rendering informed consent to participate in the study. 2. Participants with at least 20 permanent teeth present in the mouth with Generalized periodontitis as per American Academy of Periodontology / European Federation of Periodontology 2017 classification, defined as having 30 percent of the teeth examined with probing depth greater than 4mm, bleeding on probing, clinically evident attachment loss and radiographically evident bone loss.
Exclusion criteria
Exclusion criteria: 1. Participants having taken anti-inflammatory drugs within the past 3 months 2. Participants having taken antimicrobial drugs within the past 3 months 3. Participants having taken nutritional supplements in the past 3 months 4. Participants taking immunosuppressant and immunomodulatory drugs 5. Participants with autoimmune disease 6. Participants with diabetes and hypertension 7. Participants consuming tobacco in any form and alcohol consumers 8. Participants with ongoing pregnancy and nursing mothers 9. Participants having undergone any periodontal treatment within the past 6 months 10. Participants having taken herbal home remedies during the past 3 months 11. Teeth with periodontal endodontic lesions
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Change in Probing depth [PD] 2. Change in Relative clinical attachment level [RCAL] 3. Change in Gingival recession [GR] Timepoint: 1. At Baseline 2. At 6 weeks from Baseline 3. At 12 weeks from Baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in T cell associated cytokines: GM-CSF [ Ganulocyte-macrophage colony stimulating factor] IFN-α [ Interferon alpha] IFN-γ [ Interferon gamma] IL-2 [ Interleukin 2] IL-4 [ Interleukin 4] IL-5 [ Interleukin 5] IL-6 [ Interleukin 6] IL-9 [ Interleukin 9] IL-10 [ Interleukin 10] IL-12p70 [ Interleukin 12] IL-17A [ Interleukin 17 A] TNF-α [ Tumor necrosis factor alpha] Timepoint: Baseline 6 weeks 12 weeks | — |
Countries
India
Contacts
Public ContactDr Vineet Kini
MGM Medical College and Hospital Navi Mumbai
Outcome results
None listed